Study explains how FluMist works

A study conducted by the Trudeau Institute finally demystifies how the nasal flu vaccine FluMist elicits protection. "Influenza infection normally induces a massive inflammatory response in the lungs that leads to significant illness and increases the susceptibility to secondary bacterial infections," explained lead author Dr. Laura Haynes. Her team found that FluMist caused an early, non-specific immune response in animal models that preps the body for an influx of virus-specific immune cells. Those immune cells help clear the virus. Haynes' team also found the immune response elicited by the nasal spray protected against both matching and non-matching influenza strains, meaning that FluMist could be used against new strains of the disease. Release

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.